vs
Side-by-side financial comparison of COMPUGEN LTD (CGEN) and EKSO BIONICS HOLDINGS, INC. (EKSO). Click either name above to swap in a different company.
COMPUGEN LTD is the larger business by last-quarter revenue ($3.5M vs $3.1M, roughly 1.1× EKSO BIONICS HOLDINGS, INC.). EKSO BIONICS HOLDINGS, INC. runs the higher net margin — -148.9% vs -410.1%, a 261.3% gap on every dollar of revenue. On growth, EKSO BIONICS HOLDINGS, INC. posted the faster year-over-year revenue change (-38.3% vs -61.8%). EKSO BIONICS HOLDINGS, INC. produced more free cash flow last quarter ($-4.5M vs $-18.8M).
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big compan...
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis (MS) or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
CGEN vs EKSO — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.5M | $3.1M |
| Net Profit | $-14.5M | $-4.7M |
| Gross Margin | — | 53.2% |
| Operating Margin | -475.1% | -143.6% |
| Net Margin | -410.1% | -148.9% |
| Revenue YoY | -61.8% | -38.3% |
| Net Profit YoY | -54.7% | -36.9% |
| EPS (diluted) | $-0.16 | $-3.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $3.1M | ||
| Q3 25 | — | $4.2M | ||
| Q2 25 | $3.5M | $2.1M | ||
| Q1 25 | — | $3.4M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | $9.3M | $5.0M | ||
| Q1 24 | $2.6M | $3.8M |
| Q4 25 | — | $-4.7M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | $-14.5M | $-2.7M | ||
| Q1 25 | — | $-2.9M | ||
| Q4 24 | — | $-3.4M | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | $-9.4M | $-2.4M | ||
| Q1 24 | $7.3M | $-3.4M |
| Q4 25 | — | 53.2% | ||
| Q3 25 | — | 60.3% | ||
| Q2 25 | — | 39.8% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 53.3% | ||
| Q3 24 | — | 53.5% | ||
| Q2 24 | 60.5% | 53.3% | ||
| Q1 24 | 17.9% | 51.9% |
| Q4 25 | — | -143.6% | ||
| Q3 25 | — | -33.2% | ||
| Q2 25 | -475.1% | -193.2% | ||
| Q1 25 | — | -101.9% | ||
| Q4 24 | — | -43.8% | ||
| Q3 24 | — | -63.9% | ||
| Q2 24 | -128.5% | -47.2% | ||
| Q1 24 | — | -86.7% |
| Q4 25 | — | -148.9% | ||
| Q3 25 | — | -33.6% | ||
| Q2 25 | -410.1% | -131.7% | ||
| Q1 25 | — | -85.7% | ||
| Q4 24 | — | -67.1% | ||
| Q3 24 | — | -50.2% | ||
| Q2 24 | -101.4% | -48.8% | ||
| Q1 24 | 284.0% | -91.3% |
| Q4 25 | — | $-3.01 | ||
| Q3 25 | — | $-0.54 | ||
| Q2 25 | $-0.16 | $-1.24 | ||
| Q1 25 | — | $-0.12 | ||
| Q4 24 | — | $-4.71 | ||
| Q3 24 | — | $-1.53 | ||
| Q2 24 | $-0.10 | $-1.99 | ||
| Q1 24 | $89505618.00 | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $35.3M | $1.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $50.3M | $9.0M |
| Total Assets | $106.5M | $20.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $2.7M | ||
| Q2 25 | $35.3M | $5.2M | ||
| Q1 25 | — | $8.1M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $8.3M | ||
| Q2 24 | $44.6M | $5.9M | ||
| Q1 24 | $39.3M | $8.8M |
| Q4 25 | — | $9.0M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | $50.3M | $10.9M | ||
| Q1 25 | — | $12.7M | ||
| Q4 24 | — | $12.7M | ||
| Q3 24 | — | $14.9M | ||
| Q2 24 | $58.3M | $12.1M | ||
| Q1 24 | $65.6M | $14.1M |
| Q4 25 | — | $20.1M | ||
| Q3 25 | — | $21.7M | ||
| Q2 25 | $106.5M | $23.2M | ||
| Q1 25 | — | $27.3M | ||
| Q4 24 | — | $26.7M | ||
| Q3 24 | — | $29.2M | ||
| Q2 24 | $110.2M | $27.0M | ||
| Q1 24 | $121.3M | $29.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.6M | $-4.3M |
| Free Cash FlowOCF − Capex | $-18.8M | $-4.5M |
| FCF MarginFCF / Revenue | -530.8% | -141.9% |
| Capex IntensityCapex / Revenue | 6.5% | 4.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-12.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-4.3M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | $-18.6M | $-3.4M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $-1.4M | ||
| Q3 24 | — | $-2.3M | ||
| Q2 24 | $39.7M | $-2.7M | ||
| Q1 24 | — | $-3.5M |
| Q4 25 | — | $-4.5M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | $-18.8M | $-3.5M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | — | $-2.3M | ||
| Q2 24 | $39.7M | — | ||
| Q1 24 | — | $-3.5M |
| Q4 25 | — | -141.9% | ||
| Q3 25 | — | -49.0% | ||
| Q2 25 | -530.8% | -169.4% | ||
| Q1 25 | — | -58.5% | ||
| Q4 24 | — | -28.6% | ||
| Q3 24 | — | -55.3% | ||
| Q2 24 | 428.3% | — | ||
| Q1 24 | — | -92.5% |
| Q4 25 | — | 4.0% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | 6.5% | 1.9% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | 0.4% | 0.0% | ||
| Q1 24 | — | 0.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CGEN
Segment breakdown not available.
EKSO
| Products | $2.3M | 75% |
| Other | $799.0K | 25% |
